Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC) Doebele, R., Horn, L., Spira, A., Piotrowska, Z., Costa, D., Neal, J., Reichmann, W., Kerstein, D., Li, S., Janne, P. ELSEVIER SCIENCE INC. 2017: S1072–S1073
View details for Web of Science ID 000413055802315